AR062726A1 - Composiciones que comprenden compuestos marcados con 18f y metodos relacionados - Google Patents

Composiciones que comprenden compuestos marcados con 18f y metodos relacionados

Info

Publication number
AR062726A1
AR062726A1 ARP070103993A ARP070103993A AR062726A1 AR 062726 A1 AR062726 A1 AR 062726A1 AR P070103993 A ARP070103993 A AR P070103993A AR P070103993 A ARP070103993 A AR P070103993A AR 062726 A1 AR062726 A1 AR 062726A1
Authority
AR
Argentina
Prior art keywords
anion
heteroaryl
aryl
alkyl
group
Prior art date
Application number
ARP070103993A
Other languages
English (en)
Spanish (es)
Inventor
Detief Sulzle
Thomas Brumby
Lutz Lehmann
Timo Stellfeld
Ananth Srinivasan
Simon Ametamey
Original Assignee
Bayer Schering Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06090166A external-priority patent/EP1897885A1/en
Priority claimed from EP07090079A external-priority patent/EP1985624A3/en
Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag
Publication of AR062726A1 publication Critical patent/AR062726A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/655Somatostatins
    • C07K14/6555Somatostatins at least 1 amino acid in D-form
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/49Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/57545Neuropeptide Y

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Optics & Photonics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
ARP070103993A 2006-09-08 2007-09-10 Composiciones que comprenden compuestos marcados con 18f y metodos relacionados AR062726A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06090166A EP1897885A1 (en) 2006-09-08 2006-09-08 Compounds and methods for F labelled agents
EP07090079A EP1985624A3 (en) 2007-04-23 2007-04-23 Single step method of radiofluorination of biologically active compounds or biomolecules

Publications (1)

Publication Number Publication Date
AR062726A1 true AR062726A1 (es) 2008-11-26

Family

ID=39031005

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070103993A AR062726A1 (es) 2006-09-08 2007-09-10 Composiciones que comprenden compuestos marcados con 18f y metodos relacionados

Country Status (20)

Country Link
US (1) US8557776B2 (enExample)
EP (5) EP2279759A3 (enExample)
JP (2) JP5603074B2 (enExample)
KR (1) KR20090058553A (enExample)
AR (1) AR062726A1 (enExample)
AU (1) AU2007294124A1 (enExample)
BR (1) BRPI0716554A2 (enExample)
CA (2) CA2858907A1 (enExample)
CL (1) CL2007002620A1 (enExample)
CO (1) CO6150196A2 (enExample)
CR (1) CR10654A (enExample)
IL (4) IL197363A0 (enExample)
MA (1) MA30780B1 (enExample)
MX (1) MX2009002492A (enExample)
NO (1) NO20091428L (enExample)
PE (1) PE20080850A1 (enExample)
RU (1) RU2009112716A (enExample)
TN (1) TN2009000063A1 (enExample)
TW (1) TW200829277A (enExample)
WO (1) WO2008028688A2 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.
BRPI0721424A2 (pt) * 2007-03-01 2014-03-25 Bayer Schering Pharma Ag Métodos de radiofluoração
GB201013808D0 (en) 2010-08-18 2010-09-29 Ge Healthcare Ltd Peptide radiotracer compositions
WO2012094334A1 (en) * 2011-01-04 2012-07-12 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services One-step 18f labeling of biological substrates and uses of 18f labeled biological substrates
EP2717985A4 (en) * 2011-06-09 2015-02-25 Ge Healthcare Ltd DEVICE AND METHOD FOR DISTILLATION
CN108558939B (zh) * 2013-03-15 2021-08-24 癌靶技术有限责任公司 18f-标记的靶向psma的pet成像剂
GB201314936D0 (en) 2013-08-21 2013-10-02 Ge Healthcare Ltd Radiolabelling method
GB201322456D0 (en) 2013-12-18 2014-02-05 Ge Healthcare Ltd Radiotracer compositions and methods
WO2018152339A1 (en) * 2017-02-17 2018-08-23 Yale University Radiolabeled pharmaceuticals and methods of making and using same
TW202426655A (zh) 2017-07-11 2024-07-01 美商新索思股份有限公司 非天然核苷酸之導入及其方法
MA49767A (fr) 2017-08-03 2021-05-26 Synthorx Inc Conjugués de cytokine pour le traitement de maladies auto-immunes
US20210238124A1 (en) * 2018-04-20 2021-08-05 The General Hospital Corporation Acetylated prodrugs for delivery across the blood-brain barrier
CA3127689A1 (en) 2019-02-06 2020-08-13 Synthorx, Inc. Il-2 conjugates and methods of use thereof
CN113150065B (zh) * 2021-03-11 2022-07-08 武汉英纳氏药业有限公司 一种合成肽及其应用
US20240277876A1 (en) * 2021-05-20 2024-08-22 The Regents Of The University Of California Pet imaging tracers
EP4692065A1 (en) 2023-03-31 2026-02-11 Nissan Chemical Corporation Pyrazole compound and harmful organism control agent

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2795449B2 (ja) * 1987-09-24 1998-09-10 ジ・アドミニストレーターズ・オブ・ザ・ツーレイン・エデュケイショナル・ファンド 治療用ペプチド
US5723578A (en) * 1987-09-24 1998-03-03 The Administrators Of Tulane Educational Fund Peptide analogs of bombesin
US5084555A (en) 1989-08-21 1992-01-28 The Administrators Of The Tulane Educational Fund An octapeptide bombesin analog
WO1990003980A1 (en) * 1988-10-14 1990-04-19 Administrators Of The Tulane Educational Fund Therapeutic peptides
JP2846463B2 (ja) * 1989-06-02 1999-01-13 ジョージタウン・ユニバーシティー 抗ストレプトキナーゼ抗体の検出方法
US6232071B1 (en) 1990-06-11 2001-05-15 Gilead Sciences, Inc. Tenascin-C nucleic acid ligands
US5244883A (en) 1990-11-29 1993-09-14 The Administrators Of The Tulane Educational Fund Nonapeptide bombesin antagonists
TW432073B (en) * 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
AP2000001856A0 (en) 1997-12-24 2000-09-30 Vertex Pharma Prodrugs of aspartyl protease inhibitors.
WO1999033795A1 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
AU2010299A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
US6639076B1 (en) * 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
ES2248084T3 (es) * 1999-06-14 2006-03-16 Eli Lilly And Company Inhibidores de serinproteasa.
US7115766B2 (en) * 2000-11-30 2006-10-03 Indiana University Research & Technology Corp. Nucleophilic approach for preparing radiolabeled imaging agents and associated compounds
GB0115927D0 (en) 2001-06-29 2001-08-22 Nycomed Amersham Plc Solid-phase nucleophilic fluorination
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
EP1497316B1 (en) 2002-04-09 2006-07-05 Eli Lilly And Company Growth hormone secretagogues
AU2003250899A1 (en) * 2002-08-09 2004-03-11 Astellas Pharma Europe B.V. Compounds binding to p-selectin
US20080063599A1 (en) 2002-11-18 2008-03-13 Jorge Setoain Quinquer Compounds Which Can Be Used To Diagnose And Monitor Diseases Associated With The Formation Of Amyloid Protein Fibrils
US7342095B2 (en) * 2003-02-20 2008-03-11 University Of South Florida Peptidomimetic inhibitors of STAT activity and uses thereof
GB0305704D0 (en) 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
WO2006083424A2 (en) 2004-12-28 2006-08-10 The Trustees Of Columbia University In The City Of New York Radiolabeled compounds and uses thereof
JP2009505962A (ja) 2005-07-29 2009-02-12 バイエル・ヘルスケア・エルエルシー 肥満を治療するためのビフェニルアミノ酸誘導体の製造および使用
US20080029548A1 (en) 2006-05-05 2008-02-07 Ann De Wree Fabric treatment dispensing package
MX2009002492A (es) 2006-09-08 2009-08-28 Bayer Schering Pharma Ag Agentes que comprenden compuestos marcados con 18f y metodos relacionados.

Also Published As

Publication number Publication date
EP2063918A2 (en) 2009-06-03
MA30780B1 (fr) 2009-10-01
EP2455105A3 (en) 2012-09-05
IL211033A0 (en) 2011-04-28
CA2858907A1 (en) 2008-03-13
CA2662449A1 (en) 2008-03-13
NO20091428L (no) 2009-06-03
IL211527A0 (en) 2011-05-31
IL211526A0 (en) 2011-05-31
US20080292548A1 (en) 2008-11-27
JP2014028813A (ja) 2014-02-13
JP5603074B2 (ja) 2014-10-08
EP2455105B1 (en) 2016-02-17
KR20090058553A (ko) 2009-06-09
TW200829277A (en) 2008-07-16
PE20080850A1 (es) 2008-09-02
EP2279759A3 (en) 2013-04-17
EP2063918B1 (en) 2014-02-26
CO6150196A2 (es) 2010-04-20
JP2010503618A (ja) 2010-02-04
RU2009112716A (ru) 2010-10-20
EP2289564A3 (en) 2012-11-14
EP2455105A2 (en) 2012-05-23
AU2007294124A1 (en) 2008-03-13
EP3056509A1 (en) 2016-08-17
IL197363A0 (en) 2011-08-01
CL2007002620A1 (es) 2008-05-30
US8557776B2 (en) 2013-10-15
BRPI0716554A2 (pt) 2013-09-24
EP2289564A2 (en) 2011-03-02
MX2009002492A (es) 2009-08-28
WO2008028688A2 (en) 2008-03-13
CR10654A (es) 2009-04-14
TN2009000063A1 (en) 2010-08-19
EP2279759A2 (en) 2011-02-02
JP5722966B2 (ja) 2015-05-27
WO2008028688A3 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
AR062726A1 (es) Composiciones que comprenden compuestos marcados con 18f y metodos relacionados
CO6220836A2 (es) Compuestos activos biologicamnete marcados con fluoro-benzoilo 18f como agentes de diagnostico por imagenes asi como precursores de benzotriazol-1-iloxi-benzoilo2,5-dioxo-pirrolidin-1-iloxi-benzoilo y trimetilamonio benzoilo
Kang et al. Copper-catalyzed trifluoromethylthiolation of aryl and vinyl boronic acids with a shelf-stable electrophilic trifluoromethylthiolating reagent
AR073892A1 (es) Proceso de preparacion de inhibidores de sglt
HRP20191249T1 (hr) Procesi za pripremu (s)-1-(3-etoksi-4metoksifenil)-2-metansulfoniletilamina
BR102013003576A2 (pt) Métodos de produzir compostos de sulfilimina
RU2580915C2 (ru) Пламегасящая композиция, содержащая органическую кислоту
Tao et al. Synthesis and host-guest properties of pillar [6] arenes
IL264541A (en) History of sulfamolepyrolamide and their use as drugs for the treatment of jaundice b
AR074705A1 (es) Procedimiento de preparacion de benzociclobutenos funcionalizados, intermediarios y aplicacion en la sintesis de la ivabradina y de sus sales de adicion a un acido farmaceuticamente aceptable
AR079491A1 (es) Metodos de sintesis de inhibidores del factor xa tal como el betrixaban y composiciones farmaceuticas que contienen la base libre de betrixaban o su sal sustancialmente pura.
AR049401A1 (es) Aza-biciclononanos
KR20040078078A (ko) 강화액소화약제의 조성물
AR054088A1 (es) Triazoles como inhibidores de proteinquinasas. composiciones farmaceuticas
AR071592A1 (es) Fenoxibenzamidas sustituidas
AR087470A1 (es) Derivados imidazolicos bifenilenicos y composiciones farmaceuticas que los contienen
Nurminen et al. Mechanisms of the substitution reactions of phosphoramidites and their congeners
Maciejewski et al. Synthetic Methods for Preparing Ionic Liquids Containing Hypophosphite and Carbon-Extended Dicyanamide Anions.
Liu et al. Efficient synthesis of unsymmetrical S-(bromodifluoromethyl) diarylsulfonium salts for electrophilic bromodifluoromethylating reagents
CN108478980A (zh) 一种泡沫灭火剂
CN104844535A (zh) 用于制备稠合杂环离子通道调节剂的方法
CN104558039B (zh) 一种磷氮膨胀型阻燃剂及其制备方法
AR107418A1 (es) Proceso para la preparación de ácidos 4-alcoxi-3-hidroxipicolínicos
AU2014273869B2 (en) Broad temperature performance chemiluminescent systems and methods
Lee et al. Direct Trifluoromethoxylation of Aromatics and Heteroaromatics

Legal Events

Date Code Title Description
FB Suspension of granting procedure